USC Trial Finds 2,000-mg Fish Oil Fails to Slow Alzheimer's Changes
Updated
Updated · ScienceDaily · Jun 29
USC Trial Finds 2,000-mg Fish Oil Fails to Slow Alzheimer's Changes
3 articles · Updated · ScienceDaily · Jun 29
Summary
A two-year, placebo-controlled trial in 365 adults aged 55 to 80 at elevated Alzheimer's risk found high-dose DHA supplements did not improve memory, cognition or hippocampal shrinkage versus placebo.
DHA still reached the brain: cerebrospinal fluid levels rose 17% after six months, showing the fish oil was absorbed but produced no measurable brain-health benefit.
The study targeted people who rarely ate fish, with 47% carrying the APOE4 Alzheimer's risk gene, strengthening the test of whether supplements could help a vulnerable group.
USC researchers said the results undercut fish oil pills as an Alzheimer's prevention strategy and shift attention toward Mediterranean-style diet, exercise, sleep and overall health.
Fish boosts brain health while supplements fail. What is the crucial delivery secret our brains are hiding?
Could your bone health be an early warning sign for your genetic risk of Alzheimer's disease?
High-Dose Fish Oil Fails to Prevent Alzheimer’s: Major Clinical Trial Shifts Focus to Lifestyle Interventions
Overview
A major clinical trial led by Keck Medicine of USC explored whether high-dose fish oil supplements, specifically DHA, could slow memory loss or brain changes in older adults at risk for Alzheimer’s disease, especially those with the APOE ε4 gene who often have lower DHA levels. Although the supplements successfully increased DHA in the brain, they did not slow cognitive decline or prevent Alzheimer’s-related changes. The findings highlight that simply raising omega-3 levels is not enough for prevention, and suggest that a broader, lifestyle-focused approach is needed to support brain health and reduce Alzheimer’s risk.